Zealand Pharma — November 2023
-
ZEAL - Financial Results for the First Nine Mont of 2023 https://www.proinvestor.com/boards/116627
-
"Financial
Solid financial position. * Milestone payments from existing partnerships were recognized in the third quarter of 2023, with cash inflow expected in the fourth quarter of 2023, contributing to the company's solid financial position. These potential milestones include EUR 30 million from Boehringer Ingelheim associated with survodutide and USD 10 million from Sanofi associated with lixisenatide".
-
God morgen og tak for god update
-
Zealand Pharma: Milepælsbetalinger skæppede pænt i kassen i tredje kvartal https://www.proinvestor.com/investornyt/1076634/zealand-pharma-milepaelsbetalinger-skaeppede-paent-i-kassen-i-tredje-kvartal
-
Zealand Pharma Announces Financial Results for the First Nine Months of 2023:
https://ml-eu.globenewswire.com/Resource/Download/fe1d7624-d8d3-48d2-b499-430f27535d81
(PDF)
-
"Dasiglucagon in CHI ... Zealand continues to engage in partnership discussions for commercialization of the product" &
"... short bowel syndrome with intestinal failure and subsequently engage in more detailed partnership discussions"- Så JA, der er damp under kedlerne mht. detaljerede partnerskabsdrøftelser!
-
God morgen
Ja, så kom regnskabet for Q3 og her er ingen større overrraskelser så vidt jeg har kunne se til nu. Det er godt at de har fået de 30 mio euro fra BI på bog. Jeg var bange for at dette var blevet trukket til Q4 fordi studiernes først patient kommer her. Det er også godt at se at der kom 10 mio euro fra Sanofi. -
Projektet med ZP10068 (Complement Inhibitor) bliver omtaklt med "Subsequent regulatory, clinical and development efforts will be led and conducted by Alexion.". Det siger jo ikke meget om hvad der sker her.
-
ZP9830, (Ion Channel Blocker) er klar for at kunne gå i first-in-human clinical trials i 2024. Det er positivt.
-
Spørgsmål til vores Q&A er meget velkommen.
-
AstraZeneca Reaches Obesity Drug Deal; Imfinzi Combination Meets Main Goal In Liver Cancer Trial https://www.proinvestor.com/investornyt/1076681/astrazeneca-reaches-obesity-drug-deal-imfinzi-combination-meets-main-goal-in-liver-cancer-trial
-
AZ avtalen giver Eccogene en upfront payment på $185 million og $1.825 mia $ i fremtidige kliniske, regulatoriske og komercielle milepæle milestones og royalty på salg. Bemærk dette selskab har ingen lægemiddelkandidater i pipeline der er længere end fase I.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind